Best Life Sciences Platforms and Tools Companies in China
The 378 best Life Sciences Platforms and Tools companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MGI.
China's Life Sciences Platforms and Tools sector is bigger than most people realize, and this directory ranks the best companies operating in it by disclosed equity funding and recent funding momentum. We're tracking 378 companies with a combined $5.6B in disclosed capital, which tells you the market's serious even without a single unicorn on the board.
The global backdrop gives that number real weight. The life sciences platforms and tools market sat at $89.4B in 2020 and is forecast to reach $183.8B by 2027, a 10.8% CAGR driven by advances in mass spectrometry resolution and information sciences. Akeso leads our China cohort at $195M in disclosed funding, with KYinno at $35M and Benyao Technology at $29M rounding out the upper tier. So where's the concentration risk? Regulatory friction remains a structural drag on timelines across the sector, something you'll want to factor in when sizing up any platform play here. Qiming Venture Partners and Yuanbio Venture Capital are the most active names writing checks, which signals where institutional conviction is actually landing right now.
- ResearchAndMarkets.com
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in China
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | MGI Provider of gene sequencing instruments, reagents, equipment, and related products | $1.0B | 72 mo ago | Series B | 2,805 | 2016 | 19 patents Integrated microfluidic sequencing devices with temperature control, reagent cartridges, and chemiluminescent reagents | — |
| 2 | BGI Provider of services in genome sequencing | $300M | 63 mo ago | Public | 7 | 1999 | — | 1 launch · 1 partnership |
| 3 | Sangon Biotech Provider of research services and reagents and kits | $300M | 37 mo ago | Series B | 951 | 2003 | — | — |
| 4 | Geneplus Technology Developer of next-generation devices and reagents for laboratories | $220M | 58 mo ago | Series C | — | 2015 | — | — |
| 5 | Cathay Biotech Producer of industrial biotechnology polymers and solvents | $213M | 126 mo ago | Series B | 2,324 | 1997 | 276 patents Patents concentrated in chemistry & materials | — |
| 6 | CF PharmTech Chinese, commercial-stage, specialty Respiratory-focused drug-delivery development company and CDMO | $206M | 71 mo ago | Public | 550 | 2007 | 40 patents Advanced aerosol drug delivery systems and formulation technologies for inhalable therapeutics. | — |
| 7 | Transcenta Developer of antibody-based therapeutics | $205M | 65 mo ago | Public | 318 | 2019 | — | — |
| 8 | Akeso Developer of antibody drug conjugates for the treatment of broad spectrum diseases 57Funding top 20%Growth top 35%News top 39%Market top 40% All 8 signals ▾Fundingtop 20% Growthtop 35% Newstop 39% Markettop 40% Moattop 48% Talentbottom 41% Globalbottom 38% Techbottom 35% Funding: Raised $195M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $195M | 20 mo ago | Public | 2,520 | 2012 | — | 1 launch · 1 award |
| 9 | Qi Carbon Technology Developer of single-molecule nanopore sequencing technology 48Moat top 22%Funding top 27%Talent top 41%Growth top 45% All 7 signals ▾Moattop 22% Fundingtop 27% Talenttop 41% Growthtop 45% Markettop 46% Techbottom 34% Globalbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $187M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $187M | 29 mo ago | Series C | 270 | 2016 | — | — |
| 10 | RecBio Developer of vaccines to prevent infectious disease | $172M | 66 mo ago | Public | — | 2012 | — | — |
| 11 | EdiGene Developer of genome editing technology for the treatment of cancer and genetic disease | $165M | 61 mo ago | Series B | 140 | 2015 | 103 patents Patents concentrated in chemistry & materials | — |
| 12 | GeneMind Developer of genome sequencing technology for molecular diagnosis | $158M | 34 mo ago | Series C | — | 2012 | — | 1 launch |
| 13 | Bluepha Developer of synthetic biology and biomaterial | $133M | 40 mo ago | Series B | 120 | 2016 | — | — |
| 14 | Virtue Diagnostics Provider of an in vitro assay platform for diagnostic solutions | $130M | 53 mo ago | Series B | 500 | 2019 | — | 1 job opening |
| 15 | China Cord Blood Provider of biobanking services for umbilical cord blood stem cells | $115M | 169 mo ago | Acquired | 1,202 | 2003 | — | — |
| 16 | CapitalBio Tech Developer of microfluidic chips for the treatment of multiple diseases | $113M | 71 mo ago | Series D | 2,000 | 2012 | — | — |
| 17 | PTM Biolab Developer of a technology platform for the discovery of biomarker, antibody, and proteomic analysis | $100M | 67 mo ago | Series B | 326 | 2011 | 8 patents Epigenetic lysine PTM detection reagents and capecitabine polymer‑lipid nanocarrier delivery | — |
| 18 | GemPharmatech Provider of humanized models and drug screening technologies | $82M | 69 mo ago | Public | 10 | 2018 | 24 patents Genetically engineered mouse models for disease study and humanized antibody production | — |
| 19 | Heyuan Biotechnology Developer of immune cell therapy drugs | $79M | 55 mo ago | Series C | — | 2018 | — | — |
| 20 | CMAB Biopharma Developer and manufacturer of biologic products | $72M | 98 mo ago | Acqui-Hired | 250 | 2017 | — | — |
| 21 | Shenzhen Shenyan Biotechnology Developer of automated cell processing system | $57M | 27 mo ago | Series B | — | 2014 | — | — |
| 22 | Genechem Products and services in molecular biology | $56M | 74 mo ago | Series C | 529 | 2002 | — | — |
| 23 | Murren Biotechnology Developer of microbial separation and cultivation technologies 40Moat top 22%Funding top 38%Market top 48%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 38% Markettop 48% Talentbottom 49% Globalbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $50.6M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $51M | 23 mo ago | Series C | 50 | 2015 | — | — |
| 24 | Genepoint Biological Technology Platform for cryostorage and long-term preservation | $48M | 40 mo ago | Series D | — | 2015 | — | — |
| 25 | Health Gene Technologies Provider of DNA testing solutions for diagnostic solutions | $48M | 46 mo ago | Series C | 33 | 2011 | — | — |
| 26 | TCRCure Biopharma Developer of cell therapies to treat cancer | $47M | 52 mo ago | Series B | 70 | 2016 | 51 patents Engineered immune cell therapies with synthetic cytokine signaling and checkpoint antibodies | — |
| 27 | Kangpu Developer of small molecule drugs to treat cancer, auto-immune, and inflammatory disease | $39M | 61 mo ago | Series B | 25 | 2011 | — | — |
| 28 | KYinno Provider of engineered cell lines for the discovery of oncology drugs 45Funding top 34%Market top 44%Talent bottom 49%Global bottom 29% All 4 signals ▾Fundingtop 34% Markettop 44% Talentbottom 49% Globalbottom 29% Funding: Raised $35.4M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) Market: 65 employees (top 30% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 45/100 | $35M | 6 mo ago | Series B | 65 | 2017 | — | 1 launch |
| 29 | Beijing Haosi Biotechnology Provider of services in analytical testing using mass spectroscopy | $31M | 60 mo ago | Series B | — | 2016 | — | — |
| 30 | Sniper Developer of droplet digital PCR | $31M | 56 mo ago | Series B | — | 2018 | — | — |
| 31 | Hebei Senlang Biotechnology Developer of CAR-T cell based immunotherapy for cancer | $30M | 49 mo ago | Acquired | 160 | 2017 | 21 patents Nanobody-based CAR‑T immunotherapies targeting CD7, BCMA, and CLDN18.2 for cancer treatment | — |
| 32 | Benyao Technology Robotics and artificial intelligence technology to provide automation solutions 64Funding top 37%Market top 39%AI top 45%Talent bottom 49% All 5 signals ▾Fundingtop 37% Markettop 39% AItop 45% Talentbottom 49% Globalbottom 36% Funding: Raised $29.1M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Market: 100 employees (top 20% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 64/100 | $29M | 19 mo ago | Series A | 100 | 2021 | — | 3 launchs · 1 partnership |
| 33 | Shanghai Zhongke New Life Biological Technology Provider of sequencing and bioinformatics services | $28M | 26 mo ago | Series C | 90 | 2003 | — | — |
| 34 | Hangzhou Lianchuan Biotechnology Provider of genetic testing services | $26M | 56 mo ago | Series B | 271 | 2006 | — | — |
| 35 | Zhangjiagang Wanzhongyixin Biological Technology Developer of bio-detection chips and electronic biochemical sensors | $24M | 32 mo ago | Series B | 80 | 2014 | — | — |
| 36 | Beijing Xinyi Biotechnology Manufacturer of micro-droplet digital PCR and in vitro diagnostic reagents | $23M | 27 mo ago | Series B | — | 2015 | — | — |
| 37 | Mozhuo Biotechnology Developer of microfluidic technology for diagnosis and research | $23M | 46 mo ago | Series A | — | 2016 | — | — |
| 38 | Dynamic BioSystems Developer of technologies for multi-omics single-cell analysis | $20M | 40 mo ago | Deadpooled | 150 | 2021 | — | — |
| 39 | Hangzhou Shuyang Biotechnology Developer of therapeutic antibodies and recombinant protein drugs | $20M | 46 mo ago | Series B | 180 | 2015 | — | — |
| 40 | Danyang Huichuang Medical Equipment Provider of infrared spectroscopy brain function imaging solutions | $17M | 31 mo ago | Series B | 13 | 2016 | — | — |
| 41 | Shanghai Maibang Biotechnology Developer of animal cell culture media | $16M | 50 mo ago | Series B | — | 2019 | — | — |
| 42 | ThunderBio Innovation Developer of microfluidic technology for diagnosis and research | $15M | 29 mo ago | Series B | — | 2018 | — | — |
| 43 | M20 Genomics Developer of single-cell products and related technologies | $15M | 49 mo ago | Seed | — | 2021 | — | 2 launchs |
| 44 | General Biosystems Provider of synthetic biology service platforms | $15M | 47 mo ago | Series A | — | 2014 | — | — |
| 45 | Shanghai Aqu Biotechnology Provider of life sciences instruments and services | $15M | 41 mo ago | Series A | — | 2012 | — | — |
| 46 | Yinjia Biotech Provider of protein reagents, kits, and related products for biopharmaceutical applications | $15M | 41 mo ago | Series A | — | 2020 | — | — |
| 47 | Zhuhai Kairui Biotechnology Provider of serum-free cell culture technology for research services | $14M | 43 mo ago | Deadpooled | — | 2014 | — | — |
| 48 | Convergen Pharmaceuticals Provider of a platform utilizing Generative AI to accelerate drug discovery and development for the biotech… 48Funding top 41%AI top 45%Talent bottom 45%Global bottom 33% All 4 signals ▾Fundingtop 41% AItop 45% Talentbottom 45% Globalbottom 33% Funding: Raised $10.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: generative ai rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 6 mo ago | Seed | — | 2020 | — | — |
| 49 | Chengdu Zhongke Aoge Biotechnology Developer of xenotransplantation technology for research purposes 32Talent top 38%Market bottom 44%Funding bottom 43%Global bottom 36% All 4 signals ▾Talenttop 38% Marketbottom 44% Fundingbottom 43% Globalbottom 36% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Market: 30 employees (top 50% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 32/100 | $7M | 9 mo ago | Series A | 30 | 2005 | — | — |
| 50 | Beta Pharmaceutical Technology Developer of disease diagnostic reagents 55Innovation top 32%Moat top 32%Patents top 33%Talent bottom 45% All 6 signals ▾Innovationtop 32% Moattop 32% Patentstop 33% Talentbottom 45% Fundingbottom 43% Globalbottom 29% Innovation: 49 patents (top 48% of patent-holders) · 42 filings since 2022 vs 7 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 49 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $1M | 7 mo ago | Series C | — | 2008 | 49 patents Antiviral and protein‑misfolding therapeutics using PI4K inhibitors and arsenic‑based compounds | — |
Top 12 Life Sciences Platforms and Tools companies in China
#1
Series B · Beijing, Beijing · founded 2017 · 65 employees$35.4Mraised▾
Provider of engineered cell lines for the discovery of oncology drugs. The service portfolio of the company includes Engineered custom cell line development, Cell-based assay, and drug screening, Antibody-drug discovery, and Cancer cell panel profiling and Biomarker discovery.
- Dec 2025Series B$35.4M
- Nov 2021Series A—
#2
Seed · Suzhou, Jiangsu · founded 2020$10Mraised▾
Provider of a platform utilizing Generative AI to accelerate drug discovery and development for the biotech and pharmaceutical industries. It utilises the power of Large Language Models specifically trained on biological languages to discover and develop effective drugs.
- Dec 2025Seed$10M
#3
Public · Zhongshan, Guangdong Province · founded 2012 · 2520 employees$195Mraised▾
Developer of antibody drug conjugates for the treatment of broad spectrum diseases. The company utilizes proprietary Tetrabody technology to develop pipeline of products for cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields.
- Oct 2024Post IPO$249.9M
- Nov 2019Series D$150M
- Oct 2018Series C—
- Aug 2017Series B$45M
#4
Series A · Chengdu, Sichuan Sheng · founded 2005 · 30 employees$7Mraised▾
Developer of xenotransplantation technology for research purposes. The company has developed a technology to humanize pig cells that will grow into human-compatible organs. The company's technology is based on the next-generation genome engineering tool, somatic cell cloning, embryo transfer, etc.
- Sep 2025Series A—
- Jul 2024Series A—
- Sep 2021Series A$7M
#5
Series C · Wuxi, Jiangsu · founded 2008$1.4Mraised▾
Developer of disease diagnostic reagents. The company focuses on the development and labeling services of radioisotope-labeled compounds such as C14 and detection reagents for disease detection by tandem mass spectrometry.
- Oct 2025Series C$14M
- Oct 2022Seed$1.4M
#6
Series A · Shanghai, Shanghai · founded 2021 · 100 employees$29.1Mraised▾
Robotics and artificial intelligence technology to provide automation solutions. It also offers modular products for the life sciences industry.
- Oct 2024Series A—
- Apr 2023Series A$29.1M
#7
Series C · Beijing, Beijing · founded 2015 · 50 employees$50.6Mraised▾
Developer of microbial separation and cultivation technologies. It has developed Eco-screening TM technology, fungal high-density solid fermentation technology foroxygen, H2O, pH value, carbon, & nitrogen source, and microfilm coating technology on the surface of seeds to stop the damage of microorganisms. It has applications in biological agriculture, human microbiome research biomedicine, and gene discovery.
- Jul 2024Series C$41.3M
- Feb 2020Series B—
- Jun 2018Seed$9.3M
#8
Series C · Chengdu, Sichuan Sheng · founded 2016 · 270 employees$186.7Mraised▾
Developer of single-molecule nanopore sequencing technology. Genome sequencing has been developed for precision medicine and in the fields of NIPT, IVF, liquid biopsy, newborn examination, genetic disease, rare disease research, and tumor classification.
- Dec 2023Series C—
- Dec 2022Series C$101M
- Jun 2021Series B$62.5M
- May 2020Series A$14.1M
#9
Series B · Shanghai, Shanghai · founded 2003 · 951 employees$300Mraised▾
Provider of research services and reagents and kits. The company offers services like oligos, genes, and peptides syntheses, DNA and NGS sequencing, protein, antibody, and molecular biology-related services. It also sells PCR, enzyme, and other reagents, ELISA, PCR, and other kits.
- Apr 2023Series B$290M
- Aug 2010Series A$10M
#10
Series C · Shenzhen, Guangdong Province · founded 2012$158Mraised▾
Developer of genome sequencing technology for molecular diagnosis. The products include high-throughput gene sequencers, single-molecule gene sequencers, kits for non-invasive prenatal screening, preimplantation genetic testing, tumor, and genetic disease diagnosis. The company's technology includes sequencing optical systems, synthetic sequencing chemical systems, and sequencing chips.
- Aug 2023Series C$55.7M
- Sep 2021Series B$63.6M
- Jun 2021Series B$38.7M
#11
Series B · Shenzhen, Guangdong Province · founded 2014$56.7Mraised▾
Developer of automated cell processing system. It offers the CellSep PRO system which uses gradient centrifugation for customized cell preparation. It also offers the EuLV system which is a stable cell line-based lentiviral vector production system used for cell and gene therapies.
- Feb 2024Series B$41.7M
- Jun 2022Series B$14.9M
#12
Series B · Beijing, Beijing · founded 2016 · 120 employees$133Mraised▾
Developer of synthetic biology and biomaterial. The company has microbial manufacturing technology that helps in developing bio-based products for a broad range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics, and more
- Feb 2023Conventional Debt$73.3M
- Feb 2023Series B$58.6M
- Jan 2022Series B—
- Aug 2021Series B$66.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in China
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,131 China-affiliated papers.
- Chinese Academy of Medical Sciences & Peking Union Medical College436
- Chinese Academy of Sciences315
- Sichuan University311
- Central South University298
- Shanghai Jiao Tong University287
- Gene8→544
- Transcriptome5→408
- Genome10→350
- Disease2→212
- Identification (biology)3→192
- Gene2→729
- Disease2→562
- Cancer4→402
- Mechanism (biology)1→341
- Metabolomics1→205
- Disease2→281
- Mechanism (biology)1→142
- Cancer2→119
- Epigenetics2→63
- Gene1→56
Where bioinformatics is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in China
China bioinformatics patent filing is accelerating — 29 filings from 46 assignees (2018–2025), led by Mobidrop Zhejiang, BGI Shenzhen, Intel; annual filings 1→11.
- Mobidrop Zhejiang6
- BGI Shenzhen5
- Intel4
- LI Yingrui3
- Beijing INST Of Radiation Medici2
- WANG JIAN2
- XIA Yudong2
- MGI TECH2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.